Inve US ▾
ALALNY

Alnylam (ALNY) Q1 FY26 earnings call

Earnings call· Mar 2026 (Q1 FY26)· Health Care· Apr 30, 2026

Source: earnings call transcript

Alnylam's quarter was defined by the TTR franchise crossing the billion-dollar product-revenue line, with the ATTR-CM launch of AMVUTTRA one year in still showing rapid uptake, deepening first-line preference and unusually high real-world adherence for the class. Management framed the print as fully in line with the Q1 phasing it flagged in February — demand-led U.S. growth partly masked by fewer shipping weeks, insurance reauthorizations and a deliberate Germany price reset — and reiterated full-year guidance on the expectation of accelerating sequential growth. The forward stance leans on pr

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.